Intravenous Plasma Treatment for Parkinson's Disease

Early Phase 1

Completed

• Conditions: Idiopathic Parkinson Disease
• Interventions: Biological: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors; Other: Saline

• Registration Number: NCT04202757
• Lead Sponsor: The Neurology Center

Brief Summary

This study will do a preliminary evaluation of a possible treatment for mild-to-moderate Parkinson's disease. Patients will be treated with either transfusions of plasma from young donors. or with placebo transfusions. In the following several months, Parkinson's symptoms will be monitored and compared for the two groups.

Detailed Description

This is a double-blind placebo controlled trial, designed to evaluate the efficacy of plasma from volunteer donors of ages 18-25. This young fresh frozen plasma (yFFP) will be given intravenously in two doses of 12.5 ml/kg each, with 40-56 hours between doses. In the following 24 weeks, Parkinson's symptoms will be monitored using the short version of the Stanford Presenteeism Scale (SPS-6), and a modified version of the UPDRS scale.

Study Timeline

• Study First Submitted: 2018-09-21
• Study Start: 2018-09-24
• Primary Completion: 2019-08-07
• Study Completion: 2019-08-08
• Study First Submitted QC: 2019-12-13
• Study First Posted: 2019-12-18
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Diagnosis of Parkinson's disease
• Disease duration of 1 to 5 years
• Willingness to confirm the use of adequate birth control while on the trial will be required in premenopausal women without evidence for an inability to become pregnant.
• Willingness to not start any other treatment for Parkinson's or Multiple Sclerosis during the parallel part of the trial.

Exclusion Criteria

• Other significant disease, which in the view of the study doctor may make assessment of the efficacy of yFFP difficult.
• Unstable medical conditions.
• Must weigh at least 45.5 kg. Cannot weigh more than 130 kg.
• A severe disease state diagnosis
• Litigation. Patients in litigation will be excluded only if conclusion of that litigation is imminent during the course of the study.
• If patient is pregnant or breastfeeding.
• Complete IgA deficiency.
• Rare contraindications to yFFP therapy as per summary of product characteristics.
• Receiving yFFP for other reasons.
• Ongoing drug or alcohol abuse.
• Psychiatric disorder that could, in the judgement of the site investigator, interfere with successful study participation.
• Unwillingness or inability to complete the study or an inability to understand the questionnaires being used.
• Cancer other than basal cell carcinoma within the last 5 years. However, those patients who have received definitive treatment, such as curative surgery more than 6 months ago, with no known recurrence can be included.
• A history of hypercoagulable or thrombophilic clotting abnormalities.
• A history of thromboembolic events: ischaemic stroke, confirmed myocardial infarction, pulmonary embolism; deep venous thrombosis except where immobility related (for example, after injury or operation).
• Unstable angina pectoris.
• Medications that might react with yFFP such as blood thinners
• Renal failure or serum creatinine greater than 1.5 times the upper limit of normal at screening.
• Any medical condition that, in the opinion of the investigator, would make it unsafe for the patient to participate or which would interfere with assessment of the outcome measures.
• Participation in another interventional trial within 3 months of randomization. Participation in non-interventional studies is not a reason for exclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Young Fresh Frozen Plasma (yFFP)	[21CFR640.30] Plasma from 18 - 25 year old volunteer donors	\[21CFR640.30\] Plasma from 18 - 25 year old volunteer donors
Saline	Saline	0.1% riboflavin in normal saline

Primary Outcome Measures

Name	Time	Method
Changes in Physician assessment	Two weeks prior to infusion, at one-three-six months post-infusion	Unified Parkinson Disease Rating Scale (UPDRS)
Patient assessment	Two weeks prior to infusion, at one-three-six months post-infusion	Changes in Stanford Presenteeism Scale (SPS)

Secondary Outcome Measures

Name	Time	Method
Stability of administration	At the time of infusions, day 1 and day 2	Adverse events (if any)
Factors predicting a beneficial response	After the last participant's final contact at 6 months	Patient Global Impression of change

Trial Locations

Locations (1)

The Neurology Center; 🇺🇸 Houston, Texas, United States